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Serum-free culture methods for patient-derived primary glioma cultures, selecting for glioma stem-like cells (GSCs), are becoming
the gold standard in neurooncology research.These GSCs can be implemented in drug screens to detect patient-specific responses,
potentially bridging the translational gap to personalized medicine. Since numerous compounds are available, a rapid and reliable
readout for drug efficacies is required. This can be done using approaches that measure viability, confluency, cytotoxicity, or
apoptosis. To determine which assay is best suitable for drug screening, 10 different assays were systematically tested on established
glioma cell lines and validated on a panel of GSCs. General applicability was assessed using distinct treatment modalities, being
temozolomide, radiation, rapamycin, and the oncolytic adenovirus Delta24-RGD. The apoptosis and cytotoxicity assays did not
unequivocally detect responses and were excluded from further testing. The NADH- and ATP-based viability assays revealed
comparable readout for all treatments; however, the latter had smaller standard deviations and direct readout. Importantly, drugs
that interfere with cell metabolism require alternative techniques such as confluency monitoring to accurately measure treatment
effects. Taken together, our data suggest that the combination of ATP luminescence assays with confluency monitoring provides
the most specific and reproducible readout for drug screening on primary GSCs.
1. Introduction
Malignant gliomas, in particular grade IV glioblastoma
multiforme (GBM), are associated with a dismal prognosis
despite current therapy consisting of surgery, chemotherapy,
and radiation [1]. Improved treatment options are therefore
urgently needed. In the past years a vast amount of antineo-
plastic agents have been developed which may potentially
benefit glioma patients. To date, none of these promising pre-
clinical agents have demonstrated an additional value to the
current treatment regimen for which multiple reasons may
contribute. First of all, GBM has been proven to consist of
substantial interindividual and intraindividual heterogeneity
resulting in highly variable responses to treatment [2–6]. In
addition, a subpopulation of tumor initiating cells may con-
tribute to both this heterogeneity and therapeutic resistance
[7, 8]. Specific defined culture protocols have been developed
to select for andpropagate such cells, termed glioma stem-like
cells (GSCs), from freshly dissociated patient tumormaterial.
GSCs were found to better recapitulate the genotype and gene
expression patterns of human glioblastomas [9–12]. Biobank-
ing initiatives based on this model now enable the possibility
to perform paneled GSC-based drug screen experiments to
identify agents eligible for further testing in specific tumor
subgroups. Based on these insights and developments, GSCs
have become the preferred model for in vitro investigations
into new therapeutic entities for malignant glioma and may
provide an ideal platform for development of patient-tailored
medicine.
To assess the potential of new compounds in the GSC
model, a reproducible and rapid read-out of the treatment
effect on glioma cells is essential. Multiple options for
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quantification of antitumor effects are available including
cell counts, proliferation, viability, clonal growth, cytotoxi-
city, and apoptosis, using either microscopy-, absorbance-,
fluorescence-, or luminescence-based assays.
Cell death can be induced through several mechanisms of
which apoptosis, necrosis, senescence, and autophagy are to
date the best characterized [13, 14]. While apoptosis is asso-
ciated with the activation of caspases and loss of membrane
integrity, autophagy is characterized by vacuolization and
LC3 lipidation [15]. In contrast, senescent cells remain viable
but acquire morphological changes and cease to synthesize
DNA [14]. Ideally, an assay used for drug screening should
be able to capture all these forms of cell death in a reliable
manner, as the type of cell death induced by a new compound
is not always known beforehand.
We tested 10 different assays in a standardized cell line-
based in vitro model (U373 and T98) for the first selection
of suitable assays, which were subsequently validated on
GSC cultures. Four therapeutics were selected based on their
distinct mechanisms of action in antitumor activity: temo-
zolomide (TMZ), radiation, rapamycin, and the oncolytic
adenovirus Delta24-RGD. TMZ and radiation comprise the
current standard treatment regimen for glioma patients [1].
Rapamycin is an mTOR inhibitor belonging to the class
of kinase inhibitors. This agent has received widespread
attention during the last decade and is currently being
tested in clinical trials for various cancer types including
glioma [16, 17]. Delta24-RGD is an oncolytic adenovirus,
which is currently being tested in clinical phase I/II trials
for glioblastoma [18]. The cell lines U373 and T98 were
selected for the initial assay screens based on their reported
differential response to each of the therapeutic agents [19–
22]. In addition, the selected treatments have been reported
to induce various types of cell death [23–26].
In the current study, we sought to identify a drug screen-
ing assay which detects treatment response independently
of the type of induced cell death. Furthermore, generated
results must be reproducible: both intra-assay, with low
standard deviations, and interassay. Also, the assay must
have an adequate degree of discriminating capacity to clearly
differentiate responder fromnonresponder cell cultures. Next
to these intrinsic capacities, low costs and easy handling are
also important advantages for medium- to high-throughput
drug screening assays.
To make a selection of best-suited assays for rapid drug
screening, a broad range of assays, detecting caspases, LDH
release, morphology, viability, or confluency, were evaluated.
Assays that met the above-described criteria on the estab-
lished cell lines were further validated on patient-derived
GSC cultures.
2. Materials and Methods
2.1. Cell Culture. The glioma cell lines U373 and T98 were
obtained from ECACC (Salisbury, UK) and ATCC (Manas-
sas, VA), respectively. Cells were cultured in DMEM (Invit-
rogen, Breda, Netherlands), 10% FCS (Invitrogen), and 1%
Penicillin/Streptomycin (Invitrogen). Primary glioma stem-
like cell (GSC) cultures were derived from patient material
as described previously [10] and cultured in DMEM/F12
(Invitrogen), 1% Penicillin/Streptomycin, 2% B27 (Invitro-
gen), bFGF, EGF (both 20 ng/mL, Tebu-Bio, Heerhugowaard,
Netherlands), and heparin (5 𝜇g/mL, Sigma-Aldrich, Zwijn-
drecht, Netherlands). The use of patient tumor material was
acquired with informed consent frompatients as approved by
the Institutional Review Board of the Erasmus Medical Cen-
ter Rotterdam. Growth factor reduced extracellular matrix
coating (ECM, diluted 1 : 10, 10 𝜇L/well, BD Biosciences,
Breda, Netherlands) was used to grow GSC cultures in
monolayers. For the validation of the assays, GSCs were
plated at a density of 1000 cells/well in 96-well plates, which
were precoated with ECM and treated according to the below
describedmethods.TheMGMTpromotermethylation status
of the cell culture was determined as described previously
[27, 28].
2.2. Treatments. Both temozolomide (TMZ) (kindly pro-
vided by Sun Pharmaceutical Industries Ltd., Mumbai, India)
and rapamycin (Calbiochem, Darmstadt, Germany) were
dissolved in DMSO (Sigma-Aldrich) to a stock solution of
0.1M and 1mM, respectively. Further dilutions, 10, 50, and
100 𝜇M for TMZ and 10, 50, and 100 nM for rapamycin, were
prepared in medium and added to the cells. The DMSO
concentration never exceeded 0.1%. To test the effect of
radiation therapy, cells were irradiated with 3 or 6Gy using
a Cesium-137 source.
For viral treatment, the tumor selective oncolytic aden-
ovirusDelta24-RGDwas used.The construction and produc-
tion of this virus have been described previously [29, 30].
Dilutions for multiplicity of infection (MOI) 3, 10, 30 and
100 of Delta24-RGD were made in culture medium. The
GSC cultures were treated with the GFP-expressing variant
Delta24-GFP-RGD [31]; this variant was used to check for
infection efficiency.
2.3. Apoptosis Assays. For the Caspase-GLO 3/7 assay
(Promega, Leiden, Netherlands), U373 and T98 cells were
seeded at a density of 10.000 cells/well. After 16 hours of
incubation the treatment effect was measured according to
the manufacturer’s instructions using the Infinite 200 reader
(Tecan, Ma¨nnedorf, Switzerland).
As a positive control 20 nM of staurosporine (Merck
Millipore, Billerica, MA) was added to the cells. Results are
expressed as percentage of nontreated cells and error bars
indicate standard deviation.
2.4. Clonogenic Assay. For the clonogenic assay the protocol
described by Franken et al. was used [32]. Briefly, 1000
U373 cells, 500 T98 cells, or 500, 1000, or 2000 GSC cells
were seeded in T25 flasks in duplicate and treated with
TMZ, rapamycin, or radiation after 24 hours. After 10
days, cells were fixed and stained using 6% glutaraldehyde
(Sigma-Aldrich) and 0.5% crystal violet (Sigma-Aldrich).The
colonies, defined to consist of at least 50 cells, were counted by
two independent persons. Plating efficiency was determined
as the ratio of the number of colonies to the number of cells
seeded.The surviving fraction was calculated by dividing the
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number of colonies by the plating efficiency and multiplying
this by the number of cells seeded.
2.5. Cell Viability and Cytotoxicity Assays. U373 cells and
T98 cells were seeded at a density of 500 cells in 96-
well plates and incubated for 24 hours. Each experiment
was performed in triplicate. For the cell proliferation assays
(WST-1 (Roche, Basel, Schweiz), CellTiter-GLO, CellTiter-
Fluor (Promega), andAlamar Blue (Invitrogen)) as well as the
cytotoxicity assays (CytoTox-GLO,CytoTox-One (Promega))
treatment effect was measured after 5 or 6 days of incubation.
These time points were selected based on pilot time course
experiments showing clear treatment effects at these points
with control untreated cells still growing in the exponential
growth phase. All assays were performed according to the
manufacturers’ instructions. Absorption, luciferase, or fluo-
rescent signals were measured using the Infinite 200 reader
(Tecan, Ma¨nnedorf, Switzerland).
Results from the cytotoxicity assays are expressed as per-
centage of induced cytotoxicity compared to the nontreated
control; error bars indicate standard deviation. Results from
the viability assays are expressed as percentage of the non-
treated control and error bars indicate standard deviation.
2.6. Cell Count Assays. Cell confluencywas determined using
the live imaging system IncuCyte (Essen BioScience, Ann
Arbor, Michigan, USA). To this end, cells were seeded and
treated as described above, placed in the IncuCyte system
inside the incubator, and followed for the entire incuba-
tion period. Every 3 hours the system acquired an image
and confluency was measured using the algorithm in the
IncuCyte software (Essen BioScience). Results are expressed
as % confluency.
The crystal violet assay was performed as described
previously [33]. In brief, cells were seeded and treated as
described above. After 5 days of incubation the cells were
fixed using 6% glutaraldehyde (Sigma-Aldrich) and 0.5%
crystal violet (Sigma-Aldrich). The staining solution was
removed and the plates werewashed and dried overnight.The
crystal violet staining was dissolved in 10% acetic acid and
absorption was measured at 595 nm.
2.7. Analysis. For all assays, the discriminative ability (DA)
was determined by calculating the ratio between the treat-
ment effect of the responder and the treatment effect of the
nonresponder at the highest dose. Student’s 𝑡-test was used
for significance testing; 𝑝 values below 0.05 were considered
significant (GraphPad Software, La Jolla, CA, USA).
3. Results
3.1. Apoptosis Assays and Cytotoxicity Assays. A detailed
overview of all tested assays can be found in Supplemental
Table 1 of the Supplementary Material available online at
http://dx.doi.org/10.1155/2016/5623235. First, the apoptosis
and cytotoxicity assays were tested on U373 and T98 cells.
When apoptosis is induced by a certain treatment, increased
cleavage of caspase 3/7 can be detected by an increase
in luminescent signals compared to nontreated controls
(indicated by dotted line in Supplemental Figure 1). None of
the tested treatment modalities (Supplemental Figures 1(A–
D)) induced an increase in caspase cleavage in either cell
line, with the exception of the positive control staurosporine
(Supplemental Figure 1(E)), which increases measured levels
of apoptosis to 150% inU373 and 180% inT98 cells (𝑝 < 0.05).
Of the two tested cytotoxicity assays, the CytoTox-One
assay did not detect the induced cytotoxicity in the responder
cells for any of the tested treatments.TheCytoTox-GLO assay
did measure release of the dead-cell protease in treated cells;
in both irradiated and TMZ treated cells a dose-dependent
increase was noted (Supplemental Figure 2(A), T98 6Gy
𝑝 < 0.0001, Supplemental Figure 2(B), U373 100𝜇M TMZ,
𝑝 < 0.0001). Interestingly, treatment with rapamycin resulted
in lower levels of LDH and death-cell protease release in
U373 and T98, resulting in apparently lower cytotoxicity
levels in treated compared to nontreated cells (Supplemental
Figure 2(C)).
Overall, CytoTox-GLO assay did measure cytotoxicity,
although not consistently in a dose-dependent or predicted
manner. Based on these results, both the apoptosis and cyto-
toxicity assays were not further validated in primary GSCs.
3.2. Clonogenic Assay. The clonogenic assay has been
described as the gold standard for radiation-induced cell
death [32]. It measures the ability of single cells to proliferate
and form clones after treatment. As expected, the effect of
radiation on the cell lines U373 and T98 is clearly visible
as a dose-dependent decrease in the surviving fraction
(Figure 1(a) U373 6Gy, 𝑝 = 0.0031, T98 6Gy, 𝑝 < 0.0001)
with a greater effect on the radiosensitive T98 cells. The
differential sensitivity to TMZ of these cell lines was also
detected. The surviving fraction of U373 declines to almost
zero after treatment while T98 cells remain unaffected, in
accordance with reported chemosensitivity of these cell lines
[19] (Figure 1(b), 𝑝 < 0.05). Rapamycin treatment lowered
the surviving fraction in both cell lines (Figure 1(c), U373
100 nM, 𝑝 = 0.003, T98 100 nM, 𝑝 = 0.0048); however,
rapamycin also induced morphological changes in the U373
clones.The presence of scattered small clusters or single cells,
made the assessment of the clones difficult as can be seen
in the microscopic pictures of Figure 1(e). Treatment with
oncolytic virus Delta24-RGD resulted in complete loss of
clone formation at the dose of MOI 10 in the permissive cell
line U373 (Figure 1(d), 𝑝 < 0.0001).This outcomemost prob-
ably reflects ongoing viral replication during the incubation
period of clone formation. T98 cells were, as expected, not
affected by the viral treatment. Taken together, the clonogenic
assay detects treatment-induced loss of proliferative capacity
and allows discrimination between responders and nonre-
sponders. However, when a drug induces morphological
changes to the cells, results can be more difficult to interpret.
To assess the potential of the clonogenic assay in GSCs, three
GSC cultures were seeded at varying cell densities in T25
flasks and grown for 10 days. As shown in Figure 1(f), all three
GSC lines grew in dispersed manner as single cells and no
clones were formed in this period (Figure 1(f)). We therefore
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Figure 1: The clonogenic assay detects treatment effects in cell lines but not in GSCs. U373 cells (white bars) or T98 cells (black bars) were
treated with radiation (a), TMZ (b), rapamycin (c), and Delta-24RGD (d) at different doses (𝑥-axis). After 10 days clones were stained and
counted by hand and the surviving fraction was calculated. Error bars indicate standard deviation, ∗𝑝 < 0.05. Microscopic pictures of clones
(e) treated with 100 nM rapamycin (right images) and nontreated clones (left images) of U373 cells (top row) and T98 cells (bottom row).
Magnification ×10. Three primary GSCs (f) were tested for their ability to form clones over a 10-day period. Cells were plated at densities of
500, 1000, or 2000 cells/T25 flask. Magnification ×10.
conclude that the clonogenic assay is not suitable as drug
efficacy read-out for GSC cultures.
3.3. Viability Assays. A panel of viability and proliferation
assays was tested measuring either metabolic activity, live cell
protease activity, actual cell count, or monolayer confluency
(Figure 2). All assays demonstrated a decrease in viability
after radiation in a dose-dependent manner; however, the
degree of viability loss demonstrated large interassay vari-
ability. For example, viability of radiosensitive T98 cells after
3Gy irradiation varied between 85% (CTG assay) and 20%
(WST assay) (Figure 2(a), right graph). Overall, results of all
assays reflect that T98 cells are more sensitive for radiation
than U373 cells.
The differential effect of TMZ treatment on the respon-
der U373 and nonresponder T98 cells was also detected
by all tested assays (Figure 2(b)). The viability of U373
cells decreased in a dose-dependent manner between 10 𝜇M
(white bars) and 50 𝜇M (grey bars). The largest variability
between the different assay results is detected at 10 𝜇MTMZ,
especially between the viability as measured by WST (40%
decrease) and confluence as measured by the IncuCyte (IC;
no decrease). None of the tested assays reported a decrease
in viability of the resistant T98 cells upon TMZ treatment
(Figure 2(b), right graph).
Analysis of the effects of rapamycin on U373 and T98
cells revealed larger interassay variability (Figure 2(c)). All
assays revealed a reduction in viability in the rapamycin
sensitive T98 cells, with the exception of the WST-1 assay.
Also, the treatment effect of rapamycin on U373 was not
detected consistently by all assays; viability loss ranged from
approximately 60% (CellTiter-Fluor assay) to almost no
reduction (IncuCyte). Microscopic analysis of the cells, using
pictures generated by the IncuCyte, revealed morphological
changes in the cells after rapamycin treatment. As shown
in Figure 3, U373 cells treated with rapamycin were less
spindle-shaped with increased cytoplasm and smaller cell
protrusions. The T98 cells were reduced in number, grew in
clusters, and were irregularly shaped.
The viability assays were also compared in their ability to
detect the effects of oncolytic virus Delta24-RGD treatment,
in particular because the virus induces a cytopathic effect
leading to cell detachment (Figure 3, right panel), which may
influence reproducible viability assessment. In general, all
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Figure 2: Comparison of all tested viability assays. U373 cells (left column) or T98 cells (right column) were treated with (a) radiation (3Gy
(white bars), 6Gy (black bars)), (b) TMZ (10𝜇M (white bars), 50𝜇M (grey bars), and 100𝜇M (black bars)), (c) rapamycin (10 nM (white
bars), 50 nM (grey bars), and 100 nM (black bars)), or (d) Delta24-RGD (MOI 10 (white bars), MOI 30 (grey bars), and MOI 100 (black
bars)). Read-out was after 5 or 6 days with the WST-1 assay (WST), CellTiter-GLO assay (CTG), CellTiter-Fluor assay (CTF), Alamar Blue
assay with absorbance (ABa), Alamar Blue assay with fluorescence (ABf), crystal violet (CV) assay, or IncuCyte (IC). Results are expressed
as mean percentage of viability compared to nontreated controls (100%, dotted line). Error bars indicate standard deviation, ∗𝑝 < 0.05.
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Figure 3: Treatment induces morphological changes in U373 and T98 cells. Microscopic pictures made by the IncuCyte of U373 (a) or T98
cells (b) showing nontreated cells (NT) or treated cells with TMZ, rapamycin, radiation, or Delta24-RGD after 5 days.The highest tested dose
is shown, magnification ×10.
Table 1: Summary of assay results.
Assay Day Radiation TMZ Rapamycin Delta24-RGD
U373 T98 DA U373 T98 DA U373 T98 DA U373 T98 DA
Caspase 3/7 16 hr 0 0 0.9 0 0 1 0 0 1 0 0 0.9
CytoONE 5/6 0 + 1.1 0 0 0.6 0 0 0.4 ND ND ND
CytoGLO 5 +++++ +++++ 2.7 + 0 44.7 0 0 0.5 ++++ 0 2
Clonogenic 10 ++++ +++++ 0.3 +++++ 0 <0.1 ++++ +++++ 0.2 +++++ 0 <0.1
WST-1 5/6 ++ ++++ 0.2 ++++ 0 0.2 +++ 0 2 +++++ 0 0.1
CTG 5/6 ++ ++ 1.2 +++ 0 0.3 ++ +++ 0.8 +++ 0 0.5
CTF 5/6 + ++ 0.9 ++++ 0 0.3 +++ +++ 0.8 +++++ ++ 0.1
ABa 5 ++++ +++++ 0.4 ++++ 0 0.2 ++ +++ 0.5 +++++ +++++ 1.2
ABf 5 +++ ++++ 0.5 ++++ 0 0.3 + +++ 0.4 +++++ ++++ 0.5
CV 5 +++ +++++ 0.6 +++++ 0 0.2 +++ ++++ 0.5 ++++ +++ 0.2
IncuCyte 5 +++++ +++ 0.5 +++++ ++ 0.2 ++ ++ 0.4 +++++ ++ <0.1
Results are expressed by 0 = no effect, + = ↑↓ 10–20%, ++ = ↑↓ 20–40%, +++ = ↑↓ 40–60%, ++++ = ↑↓ 60–80%, and +++++ = ↑↓ 80–100%.The discriminative
ability (DA) was calculated by dividing the viability at the highest dose of the responder cell line by the viability of the nonresponder cell line. CytoONE
= CytoTox ONE, CytoGLO = CytoTox-GLO, CTG = CellTiter-GLO, CTF = CellTiter-FLUOR, ABa = Alamar Blue, absorbance, ABf = Alamar Blue,
fluorescent, CV = crystal violet.
tested assays detected a dose-response effect in the sensitive
U373 cells andmuch smaller treatment effects in the resistant
T98 cells (Figure 2(d)). However, the ABa, the ABf, and the
CV assays do detect reduced viability in the T98 cells treated
with MOI 100. Of note, CTG levels were higher compared to
the other three viability assays in U373. This probably results
from the assay procedure that, contrary to the other substrate-
based assays, does not require removal of supernatants in
which detached but still metabolically active virus-infected
cells reside.
Overall, viability and confluency assays are able to dif-
ferentiate between treatment effects in a dose-dependent
manner. However, treatments that affect the metabolism
and/ormorphology of cells or lead to detachment of cellsmay
interfere with the results of viability assays.
3.4. Comparison of All Tested Assays. The results of all tested
assays are summarized inTable 1. To quantify the discriminat-
ing ability (DA) of the assays, the ratios between the viability
of the responder and the viability of the nonresponder were
calculated for each treatment. For the assays that detect a
viability reduction, values <1 indicate a predicted difference
between responder and nonresponder: the closer to 0 the
greater the discriminative power. For the cytotoxicity and
apoptosis assays, which measure an induction compared to
the controls, values >1 indicate a difference, the higher the
better.The DA of the viability assays detecting the rapamycin
effect ranged from 0.2 (clonogenic assay) to 2 (WST-1), while
for TMZ it ranged between <0.1 (clonogenic assay) and
0.3 (CTG, CTF, and ABf), indicating a good discriminative
ability of all tested assays for TMZ. The DA for the viability
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Figure 4: Validation of the crystal violet assay on primary glioma stem-like cell cultures. The crystal violet (CV) assay was applied on four
primary glioma stem-like cell cultures. Cells were treated with 50𝜇M (white bar) or 100𝜇M (black bars) TMZ (a) and 3Gy (white bars) or
6Gy (black bars) radiation (b). Read-out was after 5 days. Error bars indicate standard deviation.
assays detecting radiation effects ranged from 0.2 (WST-1) to
1.2 (CTG). For Delta24-RGD it ranged from <0.1 (clonogenic
assay, IncuCyte) to 0.5 (CTG, ABf).
Overall, results from the crystal violet assay, clonogenic
assay, CellTiter-Fluor assay, Alamar Blue assay, and CellTiter-
GLO assay were comparable for most treatments; however,
the latter showed a better reproducibility with lower standard
deviations and the advantage of a direct read-out after
10 minutes, important benefits in high-throughput drug
screening. Also, detached cells residing in the supernatant are
included in the analysis withCTG,which can be an advantage
with certain treatments. The crystal violet assay has the extra
advantage of cost-effectiveness.
3.5. Validation of Crystal Violet and CTG Assays on Primary
Cultures. As mentioned before, the use of primary glioma
stem-like cultures (GSC) holds potential benefits over estab-
lished cell lines with regard to preclinical research on patient-
specific therapies. Therefore, we selected the most reliable
assays from the previous experiments, the CellTiter-GLO and
the crystal violet assay, and validated these on a panel of
GSCs (Supplemental Table 2) treated with TMZ, radiation,
rapamycin, or Delta24-GFP-RGD. The crystal violet (CV)
assay was first assessed for TMZ and radiation treatment on
4 GSC cultures and was found to be hampered by technical
issues rendering it unreliable in this model (Figure 4). The
crystal violet partly stains the extracellular matrix coating
used for the GSC attachment, thereby leading to inaccurate
staining and overestimation of cell numbers. Moreover,
during the fixation andwashing steps, cells detached andwere
lost, leading to large variation between triplets, as can be seen
in the error bars of Figures 4(a) and 4(b). This drawback was
most pronounced in the confluent nontreated wells, leading
to an underestimation of treatment effects.
The CellTiter-GLO (CTG) assay was tested on 8 GSCs
with three different treatment modalities (Figure 5). The
8 tested GSC lines (Supplemental Table 2) are all derived
from primary tumors and are histologically diagnosed as
glioblastoma (GBM) except for GS 144, which is derived
from an anaplastic oligodendroglioma (OD, WHO grade
III). A marker for TMZ response, the MGMT promoter
methylation status, was determined in the GSCs and revealed
both unmethylated and methylated cell cultures. The CTG
assay measured treatment effects in a reliable manner in
these lines, showing the differential response of primary
cultures to the different treatment modalities. In general,
the assay detected a larger decrease in viability in MGMT
methylated GSCs compared to MGMT unmethylated GSCs
after TMZ treatment (Figure 5(a), Supplemental Table 2).
Dose-dependent responses were also detected after radiation
and Delta24-GFP-RGD treatment (Figures 5(b) and 5(c)). In
general, response of the virus-infected GSCs also correlated
with level of infection as determined by GFP expression (not
shown). For three GSC cultures, GS79, GS149, and GS295,
the response to TMZ and rapamycin was compared between
CTG and life cell confluence imaging. Rapamycin induced
a small decrease in viability but not in a dose-dependent
manner (Figure 5(d)). For both treatments, the IncuCyte
confluence data correlated with the viability measurements
by CTG (not shown). However, as observed in U373 and
T98, the microscopic images revealed rapamycin-induced
morphological changes in the GSCs. As shown in Figure 5(e),
GS79 and GS295 cells became less spindle-shaped with
smaller cell-protrusions and a more condensed phenotype.
Taken together, the CTG assay detected differential and
dose-dependent response to all four treatment modalities
in a panel of GSCs. However, for specific agents, micro-
scopic imaging can help identify treatment effects not readily
detected by ATP measurement.
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Figure 5: Validation of CellTiter-GLO assay on primary GSC cultures. The CellTiter-GLO assay was validated on primary glioma stem-like
cell cultures. Cultures were treated with 50𝜇M (white bar) or 100𝜇M (black bars) TMZ (a), 3 Gy (white bars) or 6Gy (black bars) radiation
(b), MOI 1 (white bars), MOI 10 (grey bars), or MOI 100 (black bars) Delta-24-GFP-RGD (c), or 50, 100, 200, or 400 nM rapamycin (d).
Read-out was after 5 days. Error bars indicate standard deviation, ∗𝑝 < 0.05. Microscopic images of GS79 and GS295; nontreated (NT, left)
and treated with 400 nM rapamycin (right) (e).
4. Discussion
With the advent of personalized medicine and the increasing
availability of new compounds, the development of an in vitro
drug screening tool to select (patient-specific) effective drugs
is increasingly relevant. The presented data provides insight
into the nuances that exist between the existing viability,
cytotoxicity, and apoptosis assays. A systematic comparison
between these assays offers the opportunity to establish a
protocol for practical, sensitive, and reproducible read-out
of therapeutic efficacy of various types of treatment. We
conclude that an ATP-based viability measurement in com-
bination with microscopic imaging leads to robust detection
of therapeutic efficacy for all four treatment modalities.
There are a large number of available cell death assays,
which all focus on quite different biological phenomena,
including viability, confluency, cytotoxicity, or apoptosis.
However, defining cell death is a problem that is still under
debate and there is no gold standard to assess cell death [34],
complicating the comparison of the different assays. Never-
theless, the assays can be judged on several characteristics,
independent of induced type of cell death, which defines
their suitability for rapid drug screening.Themost important
requirement of the assay is that results should be reproducible
and the assay should be sensitive with simple and fast read-
out allowing rapid screening of large panels of compounds
and cells.
In order to compare available assays in the absence of
the expected heterogeneous responses of primary GSCs, a
first selection was made using the established glioma cell
lines U373 and T98, which both have well-defined and
distinct response profiles to various therapies as reported in
the literature. The cell line U373 is sensitive for TMZ and
Delta24-RGD, whereas T98 is resistant [19, 22]. Conversely,
T98 is more sensitive to radiation and rapamycin treatment
compared to U373 [20, 21].
The tested apoptosis and cytotoxicity assays on these
cell lines did not show reliable treatment responses (Sup-
plemental Figures 1 and 2). Although apoptosis is described
as a manner of cell death for the tested treatments, no
induction was observed at the time point recommended by
the manufacturer [23, 24]. Also the cytotoxicity assays failed
to demonstrate increases in signals, possibly indicating high
background levels of LDH release by these cells. Interestingly,
rapamycin treatment actually led to lower levels of LDH
release. This may result from a more general cell-cycle arrest
state of the cells in response to rapamycin treatment [35, 36],
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as was also shown in the metabolic activity-based assays
and microscopic images. As the induction of cell death
pathways is both time- and treatment-dependent between
(neoplastic) cells, pathway-dependent assays may be too
heavily influenced by such variables for the acquisition of
reproducible data. This suggests that these assays are not
feasible for implementation in large-scale compound screens
on panels of cell cultures but are more suitable to elucidate
mechanisms of cell death in specific research questions.
All tested viability assays detected the differential treat-
ment responses (Figure 4). The largest variability in results
was observed after rapamycin treatment. As Figures 1(e) and
3 show, rapamycin induces morphological changes in the
U373 and T98 cells whereas life cell confluency measure-
ment detected only minimal treatment effects. Most viability
assays, with the exception of the WST-1 assay, detected a
large treatment effect. The described effects of rapamycin on
cell metabolism could be responsible for this discrepancy,
since the mTOR pathway is closely related to mitochondrial
activity [37–39]. This indicates that combining a viability
assay with microscopic imaging or confluence measurement
is important to discriminate between treatment effects caus-
ing increased cell death and reduction in tumor cells versus
treatment effects causing a reduction in metabolism.
Based on its reproducibility, sensitivity, and ease of use,
the ATP-based CellTiter-GLO assay was further validated on
a panel of GSCs. Differential and dose-dependent responses
to TMZ, radiation, and oncolytic virus were observed. For
TMZ, response of the GSCs was in accordance to that
predicted by the MGMT status. As a confluency read-out
to discriminate between metabolic and cytotoxic treatment
effects, the crystal violet assay was applied. However, as the
crystal violet also stains the extracellular matrix coating,
necessary to grow GSCs in a monolayer, this assay was found
to be unsuitable for use in GSC drug screening.Therefore, for
this type of culture, live cell imaging is preferable, allowing
detection of drug-induced morphology changes, as was
observed for rapamycin and the virus-induced cytopathic
effects leading to the presence of floating cells (Figures 3
and 5(e)). Also, live cell imaging generates confluency curves
over time, which can help identify optimal time points for
viability read-out. As GSC cultures demonstrate heteroge-
neous growth rates [40] and overconfluency perturbs reliable
efficacy measurements, this is an important advantage of
combining viability assays with imaging analysis in drug
screening efforts on GSCs.
In conclusion, the present study has identified an ATP-
based luminescent viability assay combinedwithmicroscopic
imaging as the most reliable screening tool to detect the
therapeutic effect in glioma cell lines and GSCs. This pro-
tocol can be utilized for high-throughput experiments in
search of GSC response profiles for chemotherapeutics, small
molecule inhibitors, oncolytic virotherapy, and radiation
therapy. Although in vitro culture models have several short-
comings, for example, the delivery and toxicity of drugs being
not taken into account, the results can provide important
information on the response of the individual tumor cells
to specific agents. By screening large panels of patient-
derived cell cultures, identification of molecular features
related to drug response may generate predictive profiles to
a specific treatment [28, 41]. Validation of these profiles, as
well as further issues such as delivery and toxicity, should be
evaluated in in vivomodels.
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